publication . Article . 2016

sacubitril valsartan a review in chronic heart failure with reduced ejection fraction

Paul L. McCormack;
  • Published: 12 Feb 2016 Journal: Drugs, volume 76, pages 387-396 (issn: 0012-6667, eissn: 1179-1950, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan, which was recently approved in the US and the EU for the treatment of chronic heart failure (NYHA class II–IV) with reduced ejection fraction (HFrEF). In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure (composite primary endpoint) significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril. Sacubitril/...
free text keywords: Pharmacology (medical), Enalapril, medicine.drug, medicine, Ejection fraction, Heart failure, medicine.disease, Valsartan, Cardiology, medicine.medical_specialty, Sacubitril, Valsartan, ACE inhibitor, Angiotensin-converting enzyme, biology.protein, biology, business.industry, business, Internal medicine, Sacubitril
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue